Phase I metabolic genes and risk of lung cancer : multiple polymorphisms and mRNA expression by M. Rotunno et al.
Phase I Metabolic Genes and Risk of Lung Cancer:
Multiple Polymorphisms and mRNA Expression
Melissa Rotunno1, Kai Yu1, Jay H. Lubin1, Dario Consonni3,4, Angela C. Pesatori3,4, Alisa M. Goldstein1,
Lynn R. Goldin1, Sholom Wacholder1, Robert Welch2{, Laurie Burdette1,2, Stephen J. Chanock1,2, Pier
Alberto Bertazzi3,4, Margaret A. Tucker1, Neil E. Caporaso1, Nilanjan Chatterjee1, Andrew W. Bergen1,5,
Maria Teresa Landi1*
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 2Core Genotyping
Facility, Advanced Technology Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland, United
States of America, 3Department of Occupational and Environmental Health, Clinica del Lavoro ‘L. Devoto’ University of Milan, Milan, Italy, 4Department of Preventive
Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena Foundation, Milan, Italy, 5Center for Health
Sciences, SRI International, Menlo Park, California, United States of America
Abstract
Polymorphisms in genes coding for enzymes that activate tobacco lung carcinogens may generate inter-individual
differences in lung cancer risk. Previous studies had limited sample sizes, poor exposure characterization, and a few single
nucleotide polymorphisms (SNPs) tested in candidate genes. We analyzed 25 SNPs (some previously untested) in 2101
primary lung cancer cases and 2120 population controls from the Environment And Genetics in Lung cancer Etiology
(EAGLE) study from six phase I metabolic genes, including cytochrome P450s, microsomal epoxide hydrolase, and
myeloperoxidase. We evaluated the main genotype effects and genotype-smoking interactions in lung cancer risk overall
and in the major histology subtypes. We tested the combined effect of multiple SNPs on lung cancer risk and on gene
expression. Findings were prioritized based on significance thresholds and consistency across different analyses, and
accounted for multiple testing and prior knowledge. Two haplotypes in EPHX1 were significantly associated with lung
cancer risk in the overall population. In addition, CYP1B1 and CYP2A6 polymorphisms were inversely associated with
adenocarcinoma and squamous cell carcinoma risk, respectively. Moreover, the association between CYP1A1 rs2606345
genotype and lung cancer was significantly modified by intensity of cigarette smoking, suggesting an underling dose-
response mechanism. Finally, increasing number of variants at CYP1A1/A2 genes revealed significant protection in never
smokers and risk in ever smokers. Results were supported by differential gene expression in non-tumor lung tissue samples
with down-regulation of CYP1A1 in never smokers and up-regulation in smokers from CYP1A1/A2 SNPs. The significant
haplotype associations emphasize that the effect of multiple SNPs may be important despite null single SNP-associations,
and warrants consideration in genome-wide association studies (GWAS). Our findings emphasize the necessity of post-
GWAS fine mapping and SNP functional assessment to further elucidate cancer risk associations.
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Introduction
Lung cancer is the second most common malignancy and has
the highest cancer mortality rate worldwide, with an estimated
161,840 individuals expected to succumb to the disease in 2008 in
the US [1]. Tobacco smoking is the dominant causal factor for
lung cancer; however, fewer than 20% of cigarette smokers
develop the disease [2], suggesting that inherited genetic factors
may also be important risk determinants. Genetic variation at
tobacco carcinogen metabolizing enzymes may lead to inter-
individual differences in the level of internal carcinogenic dose and
to differential risk for individuals with similar exposures [3]. For
this reason, genes that encode enzymes activating harmful
chemicals are suitable candidates for lung cancer susceptibility
studies and have been intensively studied [4]. Nevertheless, the
available published data generally offer inconsistent results [5],
due to population heterogeneity, low sample size, poor character-
ization of the exposure, and a few polymorphisms tested with low
power to address the presence of their joint effects.
Here we addressed these issues in the analysis of candidate
genes in phase I metabolism and lung cancer susceptibility, taking
advantage of a large sample size and detailed epidemiological and
clinical information of the Environment And Genetics in Lung
cancer Etiology (EAGLE) study [6]. Furthermore, we integrated
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results on polymorphisms with data on expression from the same
genes and the same subjects, for the first time in the context of a
population study of phase I metabolic genes and lung cancer.
We explored the role of 25 single nucleotide polymorphisms
(SNPs) covering important genes involved in the activation of
carcinogens from cigarette smoking: cytochrome P450s (CYP1B1,
CYP1A1, CYP1A2, and CYP2A6), microsomal epoxide hydrolase
(EPXH1), and myeloperoxidase (MPO). We included also SNPs not
previously analyzed, thus providing wide loci coverage in areas
previously understudied.
Candidate genes
Many of the chemical carcinogens in tobacco smoke are
members of the polycyclic aromatic hydrocarbon (PAH) family
[7]. Cytochrome P450 enzymes activate PAHs [8] to epoxide
intermediates, which are converted by epoxide hydrolase to the
carcinogens diol-epoxides that interact with DNA or proteins to
form adducts. In human lung for example, Benzo[a]pyrene (B[a]P)
- a major carcinogenic constituent in tobacco smoke - is first
metabolically activated by cytochrome P450 1A1 (CYP1A1) and
cytochrome P450 1B1 (CYP1B1) to form B[a]P-7,8-dihydroep-
oxide, which is further hydrolyzed by microsomal epoxide
hydrolase (EPHX1) to (F)-benzo[a] pyrene-trans-7,8-dihydrodiol.
This compound is further metabolized by CYP1B1 to form
benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide [9], the most muta-
genic and carcinogenic metabolite. CYP1A1 and CYP1B1 are over
expressed in a wide range of human cancers, including breast,
colon, lung, brain and testicular cancer [10,11]. Tobacco smoking
can induce CYP1A1 and CYP1B1 proteins up to 10-fold higher
levels, particularly in subjects (about 10% of the general population)
that are more sensitive to enzyme induction [12]. Polymorphisms in
CYP1A1 (chr15q24.1) are the most frequently studied in relation to
lung cancer [13–17], but results are limited to only a few SNPs
(rs4646903, rs1048943, and rs1799814) that are more frequent in
Asian than in Caucasian populations. Functional studies for these
SNPs have predicted an increased catalytic activity and higher
levels of hydrophobic DNA adducts [18]. In close proximity and
strong linkage disequilibrium with CYP1A1 is the cytochrome
P450 1A2 (CYP1A2) gene, characterized by a similar activity [19].
Our study included 8 SNPs from the CYP1A1/A2 region not
previously studied in case-control studies of lung cancer, and some
of these SNPs were not included in the platforms used for recent
genome-wide association studies (GWAS) [20–24]. The CYP1B1
gene is located on chr2p22.2 and characterized by at least 178
SNPs (ncbi.nlm.nih.gov/dbSNP), including 4 common SNPs that
encode amino acid substitutions at codons 48, 119, 432, and 435.
These four common amino acid variants alter catalytic activity
depending on the substrate, e.g., increase for estradiol hydroxyl-
ation [25] and decrease for B[a]P epoxidation and phenylimidazo-
pyridine metabolism [26]. Relatively few studies have reported on
CYP1B1 polymorphisms and lung cancer susceptibility with
inconsistent results [27–30]. We selected 7 SNPs in CYP1B1 gene,
6 of which not previously studied in association with lung cancer.
Microsomal epoxide hydrolase (EPHX1 gene, chr1q42.12)
plays a dual role in the metabolism of PAHs and other
environmental pollutants, detoxification and bioactivation depend-
ing on the substrate. It hydrolyzes reactive compounds such as
arene, alkene, and aliphatic epoxides, which are generated by
cytochrome P450 and other phase I enzymes to the corresponding
dihydrodiols through the trans addition of water [31]. On the other
hand, less reactive dihydrodiols from PAHs can be substrates for
further transformation into dihydrodiol-epoxides such as the
carcinogen benzo[a]pyrene-7,8-diol-9,10 epoxide [32,33]. EPHX1
appears to be expressed in all tissues but the highest concentrations
have been found in the liver, gonads, kidneys, lungs, and bronchial
epithelial cells [34]. According to the NCBI’s dbSNP database, 119
SNPs have been identified in the EPHX1 gene region, 20 of which
are part of the HapMap database. Functional expression studies are
available on a limited number of these polymorphisms and showed
effects on hydrolase activity in both directions [35–37]. Few studies
have investigated the association between coding EPHX1 poly-
morphisms and lung cancer susceptibility, with disparate findings
mainly limited to the two non-synonymous SNPs rs1051740 and
rs2234922, as reported by Kiyohara et al. in their review [38] and in
more recent studies [39,40]. We included 8 SNPs from EPHX1
gene, 7 of which not previously studied in association with lung
cancer. The human cytochrome P450 2A6 (CYP2A6) is
responsible for the metabolism of different exogenous compounds
including nitrosamines, aflatoxin B1, and other xenobiotic
substrates [41]. In addition, CYP2A6 catalyzes nicotine C-oxidation
to cotinine, and the subsequent hydroxylation of cotinine to 3-OH-
cotinine [42]. Several genetic polymorphisms including point
mutations and deletions have been reported and studied in
association with lung cancer with conflicting results in populations
from different ethnicities [43–45]. In particular the polymorphism
CYP2A6 rs1801272 selected for this study, which causes an amino
acid change from Leu to His, has been object of dispute: studies
found a protective association with lung cancer and amount of
cigarette smoke [46] which has not been consistently replicated.
Myeloperoxidase (MPO gene, chr17q22) is a lysosomal enzyme
present in high concentrations in human lung due to recruitment of
neutrophils [47], and activates B[a]P [48] as well as aromatic
amines [49] in tobacco smoke and generates carcinogen-free
radicals [50]. A single base substitution, 2463G.A, in the
promoter region of MPO reduces transcription activity and DNA
adduct levels in bronchoalveolar lavages of smokers [51]. These
mechanisms have supported protective effects of the MPO 2463A
allele against lung cancer [52]. However, this possible inverse
association with lung cancer risk has remained controversial [53].
Therefore, further study of the effects of this MPO polymorphism
on lung cancer is warranted, and we included this SNP in our
selection.
A precise characterization of the smoking exposure is essential
to successfully identify molecular mechanisms involved in tobacco-
related lung carcinogenesis. The EAGLE study provides detailed
characterization of tobacco smoking including quantitative
information on total exposure and daily intake of cigarette
smoking. Using this information, we evaluated genotype-smoking
interactions by likelihood ratio test, and compared the contribu-
tions of total exposure (pack-years) and intensity (cigarettes per
day) of smoking using the linear-exponential model for smoking
excess odds ratio (EOR) [54]. This model takes into account the
correlation between the two smoking variables by describing the
EOR per pack-year in terms of delivery rate of exposure. Our
analyses also included stratified groups based on major lung cancer
histology subtypes. Furthermore, we tested whether the overall
lung cancer risk was determined by the combined action of
multiple SNPs within the same gene, despite possible null effects in
single SNP associations. We analyzed multiple SNPs jointly and
performed gene haplotype analysis. The information on gene
expression was limited to a subgroup of 44 subjects with
adenocarcinoma, but can help clarify biological mechanisms
behind the measured associations of lung cancer with polymor-
phisms in phase I metabolic genes. We prioritized our findings
based on a low p-value threshold (p-value#0.01) and consistency
across different analyses. In order to address concerns related to
multiple testing and a priori knowledge considerations, we
computed the False Positive Report Probability (FPRP) [55].
Phase I Metabolic Genes
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Results
Gene polymorphism and population characteristics
The 25 SNPs selected from phase I metabolic genes are
presented in Table 1. The gene coverage is described in
Supplemental Figure S1. All analyses were restricted to subjects
with at least a 90% genotype call rate (i.e. 34 subjects were
excluded). All 25 SNPs passed the test for Hardy-Weinberg
equilibrium genotype proportions among the 2041 controls, with a
p-value of 0.05 as the threshold.
Table 2 shows the frequency distributions and lung cancer
association estimates for the main covariate, among the 4016
subjects included in the study. Age, sex and residential area were
unrelated to case status, since frequency matching on these factors
was in the design. As expected, all smoking related variables were
associated with lung cancer, with increasing risks by increasing
smoking exposures. Recent former smokers (up to 5 years) showed
a higher risk for lung cancer compared to the current smokers.
This is likely an artifact due to the fact that people typically quit
smoking because of pre-clinical symptoms of lung cancer rather
than a reflection of increasing risks in those who quit smoking [56].
In the analyses of genetic association we added the covariate
‘‘years since quit smoking’’ to the model, to adjust both for this
reverse causation and for the attenuation of the risk over time.
SNP and lung cancer risk overall and by histology
Table 3 reports results with ptrend#0.05 for the main effect
associations between each SNP and lung cancer risk overall and by
histology. The complete list of results is reported in Supplemental
Table S1.
In adenocarcinoma cases only (test for heterogeneity by
histology: pheterog = 0.066), the minor allele of CYP1B1
rs10175368 was significantly protective for lung cancer
(OR=0.8, 95%CI= 0.69–0.93, ptrend = 0.003) and a similar
protective effect was nominally significant (i.e. p-value#0.05) for
the CYP1B1 rs9341266 polymorphism. The cumulative number of
variants in CYP1B1 rs9341266 and CYP1B1 rs10175368 also
conferred a significant protection for lung cancer in adenocarci-
noma cases only (OR=0.83, 95%CI= 0.74–0.94, ptrend = 0.002;
test for heterogeneity by histology: pheterog = 0.058), in concor-
dance with the two results from the single SNP analyses.
The CYP2A6 rs1801272 polymorphism was significantly
associated with a decreased lung cancer risk in squamous cell
carcinoma cases (OR=0.47, 95%CI=0.27–0.81, ptrend = 0.007;
Table 1. List of studied genes, polymorphisms, and corresponding characteristics.
Chromosome Gene dbSNP (a) SNP Region/Base Change (a)
AminoAcid
Change (a) Minor Allele (b) MAF (b)
1q42.12 EPHX1 rs2854455 IVS121464T.C C 0.251
rs3766934 IVS121409G.T T 0.097
rs2292566 Ex328G.A Lys119Lys A 0.138
rs2260863 IVS3+114C.G G 0.326
rs2234922 Ex4+52A.G His139Arg G 0.196
rs34143170 Ex6+19C.T His247His T 0.06
rs2292568 Ex6280C.T Pro284Pro T 0.042
rs1051741 Ex8+31C.T Asn357Asn T 0.102
2p22.2 CYP1B1 rs163077 *12259C.T T 0.217
rs9341266 Ex321249C.T (39 UTR) T 0.06
rs162562 Ex3+939A.C (39 UTR) C 0.157
rs1800440 Ex3+315A.G Asn453Ser G 0.201
rs162557 22919C.T (upstream) T 0.17
rs162556 23922T.C (upstream) C 0.446
rs10175368 25329G.A (upstream) A 0.282
15q24.1 CYP1A1 rs2198843 11599 bp 39 of STP G.C (intergenic) C 0.17
rs2606345 IVS1+606T.G G 0.358
rs2470893 24010G.A (upstream) A 0.204
rs12441817 210375A.G (intergenic) G 0.079
rs2472297 212441G.A (intergenic) A 0.115
rs2472299 217961C.T (intergenic) T 0.321
15q24.1 CYP1A2 rs11072508 14967 bp 39 of STP T.C (intergenic) C 0.388
rs4886410 *18214C.G (intergenic) G 0.383
19q13.2 CYP2A6 rs1801272 Ex3215T.A Leu160His A 0.041
17q22 MPO rs2333227 2642G.A (upstream) (aka 2463
promoter)
A 0.255
(a) According to SNP500 database.
(b) Minor Allele and Minor Allele Frequency (MAF) are based on EAGLE controls.
doi:10.1371/journal.pone.0005652.t001
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Table 2. Characteristics of lung cancer cases and controls from the EAGLE population with genotype call rate $90%, and their
association with lung cancer status.
Characteristic Sub-category Cases Controls
Association with
case:control status
n % n % OR [95%CI]#
Sex (a)
Males 1563 79.1 1560 76.4 1.0
Females 412 20.9 481 23.6 0.88 [0.76–1.03]
Age (b)
35–39 11 0.6 15 0.7 1.0
40–44 17 0.9 26 1.3 0.88 [0.33–2.39]
45–49 50 2.5 67 3.3 1.03 [0.44–2.46]
50–54 124 6.3 121 5.9 1.39 [0.61–3.18]
55–59 222 11.2 289 14.2 1.03 [0.46–2.31]
60–64 337 17.1 356 17.4 1.25 [0.56–2.77]
65–69 445 22.5 472 23.1 1.24 [0.56–2.75]
70–74 442 22.4 412 20.2 1.42 [0.64–3.15]
75–79 327 16.6 283 13.9 1.56 [0.70–3.48]
Area (c)
Brescia 261 13.2 240 11.8 1.0
Milan 1302 65.9 1389 68.1 0.85 [0.71–1.04]
Monza 133 6.7 111 5.4 1.10 [0.81–1.50]
Pavia 126 6.4 122 6.0 0.96 [0.71–1.30]
Varese 153 7.7 179 8.8 0.78 [0.59–1.04]
Smoking status (d)
Never 140 7.1 658 32.2 1.0
Former, .2years 655 33.2 848 41.5 3.98 [3.18–4.98]
Former, 0.5 to 2 years 188 9.5 30 1.6 34.37 [22.22–53.16]
Current 980 49.6 501 24.5 11.37 [9.06–14.28]
Missing 12 0.6 4 0.2
Cigarettes per day (d)
Never 140 7.1 658 32.2 1.0
,12 233 11.8 519 25.4 2.54 [1.98–3.26]
12–20 358 18.1 343 16.8 7.00 [5.41–9.05]
20–25 571 28.9 290 14.2 14.77 [11.37–19.18]
.25 568 28.8 226 11.1 19.63 [14.98–25.72]
Missing 105 5.3 5 0.2
Total pack-years (d)
Never 140 7.1 658 32.2 1.0
,19.5 187 9.5 578 28.3 1.88 [1.45–2.43]
19.5–36 381 19.3 365 17.9 7.25 [5.61–9.37]
36–52.5 539 27.3 275 13.5 15.02 [11.54–19.56]
.52.5 623 31.5 160 7.8 30.79 [23.19–40.86]
Missing 105 5.3 5 0.2
Years since quit (d)
Current 980 49.6 501 24.5 1.0
,5 300 15.2 96 4.7 1.49 [1.15–1.93]
5–15 249 12.6 179 8.8 0.63 [0.50–0.78]
15–24 180 9.1 260 12.7 0.31 [0.25–0.39]
.24 114 5.8 343 16.8 0.14 [0.11–0.18]
Never 140 7.1 658 32.2 0.09 [0.07–0.11]
Missing 12 0.6 4 0.2
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test for heterogeneity by histology: pheterog = 0.045). The protective
effect was nominally significant in the overall population.
Interestingly, the same SNP was significantly associated with a
decrease of cigarette smoking intensity in controls (OR=0.86,
95%CI= 0.78–0.94, ptrend = 0.0007).
Genotype-smoking interaction
We repeated the analyses within subgroups defined by smoking
status (never and ever smokers) in all cases and controls and,
separately, in adenocarcinoma cases only and all controls (see
Table 4 for the single SNP analysis, and Supplemental Table S2
for the joint SNP analysis). The other histology groups included
too few never smokers to perform a meaningful analysis.
Three SNPs in the chr15q24.1 region (CYP1A1/A2) showed a
protective effect for lung cancer among never smokers but a
tendency towards increased risk of lung cancer in ever smokers,
with a significant genotype-smoking interaction for CYP1A1
rs2606345 (pinteract = 0.005) and a nominally significant geno-
type-smoking interaction for the two SNPs in CYP1A2.
We further explored the significant genotype-smoking interac-
tion in CYP1A1 rs2606345 by means of the linear-exponential
model for smoking excess odds ratio [54], and evaluated whether
the variation in smoking risk by genotype resulted from the
interaction with smoking intensity or with total pack-years and
whether this interaction was present among other categories of
smokers such as current or former smokers. Results are shown in
Figure 1. The EOR per pack-years in current smokers compared
to never smokers (Figure 1A and Figure 1B) increased for
increasing number of cigarettes per day, reaching a plateau for
subjects carrying the CYP1A1 rs2606345 homozygote major allele
(Figure 1A), and in contrast, increasing exponentially for subjects
carrying the CYP1A1 rs2606345 heterozygote or homozygote
minor allele (Figure 1B). The same analysis of EOR/pack-years in
former smokers versus never smokers (Figure 1C and Figure 1D)
similarly showed that the EOR increase for cigarettes per day was
lower in homozygote major allele carriers (Figure 1C) than for
heterozygote or homozygote minor alleles carriers (Figure 1D), but
here EOR/pack-years reached a plateau among both groups of
subjects. Panel E in Figure 1 reports the estimated deviances and
p-values for the genotype-smoking interaction among current and
former smokers for the model including both interaction terms
between the genotype and pack-years and between the genotype
and cigarettes per day, and for intermediate models including
either the interaction term between genotype and pack-years, or
the interaction term between genotype and cigarettes per day. The
overall genotype-smoking interaction was stronger among current
smokers (pinteract = 0.009) than among former smokers (pinteract =
0.124). Among current smokers, the removal of pack-years from
the model did not degrade fit relative to the full model (p = 0.209),
whereas the removal of cigarettes per day did degrade fit
(p = 0.022), suggesting that the genotype interaction effects
resulted from cigarettes per day and not pack-years.
In the joint analysis of multiple SNPs stratified by smoking
(Supplemental Table S2), the cumulative number of variants of all
8 SNPs from CYP1A1 and CYP1A2 in the chr15q24.1 region
conferred a significant overall risk for lung cancer in ever smokers
(OR=1.03, 95%CI=1.00–1.07, ptrend = 0.040) and a borderline
protective effect in never smokers (OR=0.91, 95%CI= 0.84–
0.99, ptrend = 0.055). The smoking-genotype interaction was highly
significant (pinteract = 0.006).
In addition, the minor allele of CYP2A6 rs1801272 showed a
significant protective effect in ever smokers, increased risk in never
smokers, and a nominally significant genotype-smoking interac-
tion.
Linkage disequilibrium and haplotype analysis
For genes represented by two or more SNPs, we computed
linkage disequilibrium (LD) among controls and haplotype
association with lung cancer. The complete results are reported
in the Supplemental Text S1 and Figure S2.
Interestingly, the haplotype analysis for the 8 SNPs in EPHX1
(which were in low LD: r2#0.1 for most SNPs pairs, r2 = 0.43 for
EPHX1 rs2234922 and EPHX1 rs1051741) revealed two haplo-
types significantly associated with lung cancer in the overall
population: carriers of TGGCACTC haplotype had higher risk than
non-carriers (freq = 0.01, p-value = 0.010) and carriers of CGGC-
GCCT haplotype had a lower risk than non-carriers (freq = 0.01, p-
value = 0.015). In addition, we found similar results in the analysis
restricted to adenocarcinoma cases only: TGGCACTC (p-value =
0.008) and CGGCGCCT (p-value = 0.023). Since the 8 SNPs were
Characteristic Sub-category Cases Controls
Association with
case:control status
n % n % OR [95%CI]#
Histology
Adenocarcinomas 809 41.0
Squamous cell carcinoma 505 25.6
Small cell carcinoma 201 10.2
Others 425 21.5
Missing 35 1.8
Total 1975 100.0 2041 100.0
#Two-sided Wald test.
(a) ORs adjusted for age and area.
(b) ORs adjusted for sex and area.
(c) ORs adjusted for sex and age.
(d) ORs adjusted for sex, age and area.
doi:10.1371/journal.pone.0005652.t002
Table 2. cont.
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in low LD, we also performed a three marker moving window
haplotype analysis and found no significant associations between
lung cancer and haplotype combinations of three SNPs (see
Supplemental Table S3). However, we identified a borderline
significant protective association (freq = 0.03, p-value = 0.059) with
a three-locus haplotype with a C, G, and T in locus 1, 2 and 8,
respectively, which was also contained in the 8 SNP haplotype.
For the 8 SNPs in the chr15q24.1 region, we found two regions
of LD, one of modest strength surrounding CYP1A1, and a second
region 39 of CYP1A2 (see Supplemental Figure S2), concordant
with the results from HapMap. Haplotype analyses were
computed separately for these two LD regions; the GTAAA
haplotype (freq = 0.07) and the CGGGG haplotype (freq = 0.03) were
nominally significantly associated with lung cancer risk in never
and ever smokers respectively.
Association between genotype and gene expression
The complete results for the correlation between genotype and
gene expression data are reported in Supplemental Table S4. We
found that the 8 polymorphisms in the 15q24 chromosomal region
had a significant down-regulating effect on mRNA expression for
CYP1A1 gene among the 14 never smokers (d=21.51, p-
value = 0.007) and showed a trend for up-regulation among the
15 current smokers (d=4.95, p-value = 0.078). The 7 polymor-
phisms in CYP1B1 were significantly associated with an increase of
mRNA expression in CYP1B1 among the 15 current smokers
(d=8.99, p-value = 0.004), and not among the 44 subjects overall.
For the 8 SNPs in EPHX1 gene, we observed an overall trend for
decreasing expression (d=21.20, p-value = 0.096), which was
nominally significant among the 15 former smokers (d=22.56, p-
value = 0.049).
Table 3. Polymorphisms associated with risk of lung cancer overall and by histology with a significant trend (in bold) or nominally
significant trend (in italics).
SNP Genotype Controls Cases OR (a) 95%CI2 95%CI+ P-value Trend#
All Histologies
CYP2A6/rs1801272 T/T 1855 1756 1
T/A 160 101 0.74 0.55 1.00
A/A 4 2 0.26 0.04 1.94
T/A+A/A 164 103 0.73 0.54 0.98
Trend 0.72 0.54 0.96 0.026
Adenocarcinoma
EPHX1/rs2292568 C/C 1852 680 1
C/T 156 86 1.48 1.09 2.01
T/T 7 1 0.41 0.04 4.43
C/T+T/T 163 87 1.44 1.06 1.96
Trend 1.38 1.03 1.85 0.032
CYP1B1/rs9341266 C/C 1798 701 1
C/T 222 72 0.8 0.59 1.09
T/T 12 1 0.14 0.01 1.24
C/T+T/T 234 73 0.76 0.56 1.04
Trend 0.74 0.55 0.99 0.046
CYP1B1/rs162556 T/T 621 205 1
T/C 1002 391 1.15 0.92 1.42
C/C 400 172 1.34 1.03 1.74
T/C+C/C 1402 563 1.2 0.98 1.47
Trend 1.16 1.01 1.32 0.031
CYP1B1/rs10175368 G/G 1056 430 1
G/A 790 297 0.87 0.71 1.05
A/A 176 45 0.55 0.38 0.81
G/A+A/A 966 342 0.81 0.67 0.97
Trend 0.8 0.69 0.93 0.003
Squamous Cell Carcinoma
CYP2A6/rs1801272 T/T 1855 463 1
T/A 160 18 0.48 0.27 0.86
A/A 4 0 - - -
T/A+A/A 164 18 0.47 0.27 0.83
Trend 0.47 0.27 0.81 0.007
(a) ORs were adjusted for age, sex, area, cigarette per day, total pack-years, years since quit smoking.
#Two-sided Wald test.
doi:10.1371/journal.pone.0005652.t003
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Multiple testing
FPRP calculations (Table 5) were performed for nominally
significant or significant single SNP analysis results. The table
shows that all prior probabilities of $0.10 had low FPRP values
(,0.5).
Discussion
In this large population-based case-control study of lung cancer
we have observed that EPHX1, CYP1A1, CYP1B1 and CYP2A6
genes may play a role in lung cancer susceptibility.
Figure 1. Estimates of the smoking excess odds ratio by CYP1A1/rs2606345 status. Estimates of the linear slope parameter (EOR per pack-
year) and its 95 percent confidence interval within categories of smoking intensity (square symbol) and fitted linear-exponential odds ratio for
continuous pack-years and cigarettes per day (solid line) for CYP1A1 rs2606345. The Figure shows results for T/T genotype in panels A and C, and for
T/G+G/G genotypes in panels B and D, among current smokers (700 T/T+997 T/G+G/G) (panels A and B) and former smokers (640 T/T+855 T/G+G/G)
(panels C and D). The table in panel E reports the estimated deviances and p-values for the genotype-smoking interaction among current and former
smokers for the model including both interaction terms between the genotype and pack-years and between the genotype and cigarette per day, and
for intermediate models including either the interaction term between genotype and pack-years, or the interaction term between genotype and
cigarette per day. The significant increase in deviance in current smokers is mainly due to the interaction term of the genotype with cigarettes per
day and not with pack-years; the removal of pack-years from the model did not degrade fit relative to the full model (p = 0.209), whereas the removal
of cigarettes per day did degrade fit (p = 0.022).
doi:10.1371/journal.pone.0005652.g001
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Two haplotypes in EPHX1 compared to all other haplotypes
were significantly associated with lung cancer in the overall
population and in adenocarcinoma cases only: TGGCACTC as a
risk factor and CGGCGCCT as a protective factor. In addition, we
identified a borderline significant protective association with a
three-locus haplotype which was also contained in the 8SNP
haplotype and was present in approximately 3% of the population.
These findings suggest that more than a hundred people in our
study carried a three-variant haplotype resulting in a decreased
lung cancer risk. The protective effect was even stronger for the
smaller number of subjects (1%) who carried a combination of
these three SNPs and the remaining 5 SNPs in the 8-locus
haplotype. Since the significant associations with lung cancer were
based on relatively rare haplotypes, replication will be needed in
order to validate this finding. None of the 8 SNPs was significantly
associated with lung cancer in the overall population when
analyzed separately. This result, if confirmed, demonstrates that
the effect of multiple SNPs on lung cancer may be important even
if most individual SNPs do not show significant association. This
may explain why previously published results, which are based on
a limited number of EPHX1 polymorphisms, were inconsistent. In
particular, EPHX1 rs2234922 has been previously associated both
with risk [39] and with protection [57] for lung cancer. This SNP
was not associated with lung cancer in our data. Nevertheless it
was one of the three SNPs that differentiate the two significant
haplotypes reported here. The other two SNPs were EPHX1
rs1051741, in medium LD with EPHX1 rs2234922, and EPHX1
rs2292568, nominally significantly associated with risk of lung
adenocarcinoma in our data (see Table 3). We did not find a
significant association between EPHX1 polymorphisms and gene
expression. Measurements of epoxide hydrolase activity in lung
cancer patients carrying these haplotypes will be needed in order
to understand the biological mechanism that underlies this finding.
A group of SNPs from two LD regions in the chr15q24.1 region
(CYP1A1 and CYP1A2) showed a protective effect on lung cancer
risk among never smokers and a suggestive risk of lung cancer in
ever smokers with a significant genotype-smoking interaction for
CYP1A1 rs2606345 and a nominally significant interaction for the
two SNPs in CYP1A2. This result was confirmed by the multiple
SNP analysis stratified by smoking. The cumulative number of
variants from CYP1A1 and CYP1A2 was in fact associated with a
significant risk for lung cancer in ever smokers and a protective
effect in never smokers, with a highly significant smoking-genotype
interaction. Interestingly, Wang et al. [58] recently reported an
analogous inverse association between CYP1A1 rs2606345 and
levels of DNA adducts: the variant allele was associated with high
level of DNA adducts among women with high PAH exposure and
with low level of DNA adducts among women with low PAH
exposure. Further, using the linear-exponential model for smoking
EOR we found that the difference in smoking effects between the
wild type and the variant resulted from the effects of cigarettes per
day and not pack-years. This finding suggests that a dose-response
mechanism and a saturation effect might underlie the smoking-
mediated association between CYP1A1 and lung cancer risk. The
gene expression analysis supported this finding. In fact, the lower
expression of CYP1A1 among never smokers and higher expression
among current smokers in association with the SNPs at
chr15q24.1 was consistent with the observed protective effect for
lung cancer among never smokers and risk among smokers in
association with variants in CYP1A1/A2.
Our data also showed that the minor allele of CYP1B1
rs10175368 was significantly protective for adenocarcinoma of
the lung (OR=0.80, 95%CI= 0.69–0.93) and a similar protective
effect was observed for the minor allele of CYP1B1 rs9341266
(r2 = 0.30), as well as for the cumulative sum of the two minor
alleles. In addition, according to the HapMap database, CYP1B1
Table 5. False positive report probability.
Gene/SNP MAF Controls Cases Test OR(**) P-value Power(*) Prior Probabilities
0.5 0.25 0.1 0.01 0.001
CYP2A6/rs1801272 0.041 2019 1859 (a) 0.720 0.026 0.772 0.033 0.092 0.233 0.769 0.971
EPHX1/rs2292568 0.042 2015 767 (b) 1.380 0.032 0.632 0.048 0.132 0.313 0.834 0.981
CYP1B1/rs9341266 0.060 2032 774 (b) 0.741 0.046 0.609 0.070 0.185 0.405 0.882 0.987
CYP1B1/rs162556 0.446 2023 768 (b) 1.156 0.031 0.673 0.044 0.121 0.293 0.820 0.979
CYP1B1/rs10175368 0.282 2022 772 (b) 0.799 0.003 0.907 0.003 0.010 0.029 0.247 0.768
CYP2A6/rs1801272 0.041 2019 481 (c) 0.467 0.007 0.926 0.008 0.022 0.064 0.428 0.883
CYP1A1/rs2606345 0.358 2028 1866 (d) 0.687 0.005 0.795 0.006 0.019 0.054 0.384 0.863
CYP1A2/rs11072508 0.388 2031 1861 (d) 0.822 0.038 0.545 0.065 0.173 0.386 0.873 0.986
CYP1A2/rs4886410 0.383 2030 1866 (d) 0.829 0.047 0.511 0.084 0.216 0.453 0.901 0.989
CYP2A6/rs1801272 0.041 2019 1859 (d) 1.508 0.026 0.757 0.033 0.093 0.236 0.773 0.972
CYP1A1/rs2606345 0.358 2028 774 (e) 0.739 0.022 0.481 0.044 0.121 0.291 0.819 0.979
FPRP values for the nominally significant (p-value,0.05) results from test of main single SNP effects (Table 3) and of SNP-smoking interaction effects (Table 4). FPRP is
computed according to the formula a(12p)/[a(12p)+(12b)p], where a and (12b) are the P-value and Power values reported in the table, and p represents the Prior
Probability ranging from 0.001 to 0.5. FPRP values less than 0.2 are in italic, FPRP values between 0.2 and 0.5 are bold, and FPRP values larger than 0.5 are the rest.
(a) Test for main genetic effect among all subjects.
(b) Test for main genetic effect among controls and adenocarcinoma cases.
(c) Test for main genetic effect among controls and squamous carcinoma cases.
(d) Test for gene-smoking interaction among all subjects.
(e) Test for gene-smoking interaction among controls and adenocarcinoma cases.
(*) OR indicates the measured odds ratio for the main genetic effect for tests (a), (b), and (c), and the measured odds-ratio ratio for the gene-smoking interaction effect
for tests (d) and (e).
(**) The statistical power to detect the measured OR given a type I error rate of 0.05 was computed by means of the QUANTO software (http://hydra.usc.edu/gxe).
doi:10.1371/journal.pone.0005652.t005
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rs10175368 is in LD with 4 other SNPs in the same chromosomal
region (rs2551188, rs4646430, rs4646429, and rs10175338, see
Supplemental Figure S1B). These 4 SNPs are likely to be
characterized by the same protective association. Previous results
on CYP1B1 polymorphisms and lung cancer have been limited to
the four non-synonymous SNPs rs10012, rs1056827, rs1056836
and rs1800440 [27–30,59,60]. None of the reported positive
findings have been consistently replicated, except for rs10012,
associated with lung cancer risk in two independent studies
[28,30]. Our data on rs1800440 did not show any significant
association with lung cancer. The three other non-synonymous
SNPs were not evaluated in the current study. However, our SNPs
were selected with an attempt to cover other regions of the gene.
According to our data, variants other than those in the coding
region could alter lung cancer risk. Polymorphisms in CYP1B1
have been associated with decreased PAH metabolism [26]. The
significant protective effect of the CYP1B1 rs10175368 variant
allele could be due to a lower level of smoking carcinogens in
subjects carrying the variant allele. We did not find a significant
effect on CYP1B1 gene expression for the two SNPs in CYP1B1
associated with a protection for adenocarcinoma. However, when
we considered all seven polymorphisms in CYP1B1 together and
studied their effect on gene expression, we found a significant
increase in CYP1B1 gene expression among current smokers. The
CYP1B1 gene is known to be highly expressed in lung tissues of
lung cancer patients. Our result supports previous findings of
CYP1B1 gene over-expression among current smokers [61] and
suggests a possible involvement of CYP1B1 polymorphisms as a
mechanism for differential expression.
The CYP2A6 rs1801272 polymorphism, which results in an
amino acid change from Leu to His, was significantly associated
with a decreased risk for squamous cell carcinoma, a strictly
smoking-related malignancy. Interestingly, the same SNP was
associated with a decrease in cigarettes per day in controls,
confirming a previously hypothesized role of this gene in tobacco
smoking addiction [46]. Our report provides the first confirmation
of this finding in a population-based sample. In addition, the A
allele of CYP2A6 rs1801272 showed a significant protective effect
in ever smokers but no effect in never smokers, with a nominally
significant genotype-smoking interaction due to the effect of
cigarettes per day and not pack-years. The CYP2A6 gene is
characterized by multiple polymorphisms and genomic repetitive
elements in the regulatory regions, which make a complete
coverage of the gene extremely challenging. Moreover, most
variants are very rare in the general population and would not be
identifiable even in a large sample size as ours. We genotyped
CYP2A6 rs1801272 (also known as CYP2A6*2) because this SNP is
relatively common (4% in our population), has been well
characterized in previous functional studies [46], and showed
controversial associations with cancer and smoking dependence
[43–46]. Our findings of an association with both lung cancer risk
and tobacco addiction warrant further investigation based on a
more complete coverage of this gene.
The size of our population provides unusual power for
confirming previously reported associations. Our data do not
support proposed associations between lung cancer and EPHX1
rs2234922, CYP1B1 rs1800440, and MPO rs2333227. The
confidence in our significant results was supported by the low
FPRP values (see Table 5) observed for prior probabilities of 0.10
or more given the strong prior probabilities of the selected phase I
genes being involved in lung cancer risk.
At the time that this project was initiated, there was less
genotype data available with which to select SNPs to cover
haplotype blocks. Nevertheless, based on the existing SNP500Can-
cer and comparative assessment of HapMap data, we selected
SNPs that represented tagSNPs in the Caucasian population.
Although the coverage is inevitably incomplete, we substantially
improved the coverage of the selected genes in comparison with
previous studies (see Supplemental Figure S1).
Strengths of our study include a population-based design, large
sample size with adequate power to detect main gene effect and
gene-smoking interaction effect, integrative analysis with gene
expression data, and a systematic approach in evaluating the joint
effects of multiple SNPs.
Our results are particularly timely in relation to recent GWAS.
For example, the significant association between haplotypes in
EPHX1 and lung cancer risk emphasizes that the effect of multiple
SNPs may be important despite null associations in single SNP
analyses, and should be taken into consideration in GWAS.
Similarly, although further study is necessary to confirm the
qualitative interaction between smoking and genotype in relation
to lung cancer susceptibility for the CYP1A1 rs2606345, this
finding is particularly interesting, considering that this SNP is not
included in the HapMap database or in the common platforms
used for GWAS, although it is in relatively strong LD with other
SNPs in these platforms. This highlights the necessity of fine
mapping after GWAS to further elucidate associations with lung
cancer risk and tobacco smoking addiction. In conclusion, this
study emphasizes the importance of ample coverage of genes in
the analysis of genetic susceptibility of cancer, integration with
corresponding gene function in the target tissue, and rigorous
study design and analytical approach.
Materials and Methods
Study population and data collection
A detailed description of the EAGLE study has been recently
published [6]. Briefly, the study includes 2101 incident lung cancer
cases and 2120 population controls enrolled in the period April
2002–June 2005 in 216 municipalities from the Lombardy region
(Italy). Cases were subjects with primary cancer of trachea,
bronchus and lung, first diagnosed between April 22, 2002 and
February 28, 2005, and admitted to 13 hospitals of the study area.
Controls were randomly sampled from population databases,
frequency matched to cases by area of residence (5 classes), gender,
and age (5-year categories), and contacted through the family
physician. All enrolled subjects were Caucasian. Subjects were 35–
79 years of age at diagnosis (cases) or at sampling/enrollment for
interview (controls). The study participation rates were 86.6%
among cases and 72.4% among controls. After signing an
Institutional Review Board-approved informed consent form,
subjects underwent a computer-assisted personal interview (CAPI)
and filled-in a self-administered questionnaire. Biospecimens
(blood or buccal rinse from all participants and pathological
samples from cases) were collected. Epidemiological information
on the 4016 EAGLE subjects with available genotype data and
analyzed in this study is described in Table 2.
SNP selection and genotyping
At the start of the study, SNP assays were selected from those
available at the Core Genotyping Facility (CGF) of the Division of
Cancer Epidemiology and Genetics (National Cancer Institute),
using our own assessment of linkage disequilibrium between the
SNPs from HapMap and previous evidence from the literature.
The 25 SNPs selected from phase I metabolism genes are
presented in Table 1. The gene coverage for EPHX1, CYP1B1,
and CYP1A1/A2 based on the present version of the HapMap
database is described in Supplemental Figure S1. For CYP2A6 and
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MPO genes, we selected only two SNPs whose association with
lung cancer has been debated in previous studies [43–45,52,53].
Genotyping of the 25 SNPs was done at the CGF with the
TaqManH assay, described at the National Cancer Institute
SNP500Cancer website (http://snp500cancer.nci.nih.gov). Geno-
typing was performed on 4050 EAGLE subjects (those with
sufficient DNA samples). Duplicate quality-control samples (2% of
the total) showed 100% agreement for all 25 assays.
Gene expression data
In addition to genotype information, we analyzed mRNA gene
expression data from an Affymetrix HG-U133A microarray using
fresh tissue samples from a subgroup of adenocarcinoma cases.
The original microarray study has been described elsewhere [61].
Here, we analyzed the gene expression data from non-tumor
samples of 44 subjects in relation to genotype data from the same
subjects, as described in the Statistical analysis section.
Statistical analysis
Most analyses were implemented and performed using the R-
project (version 2.8) statistical package (http://www.r-project.org/
index.html). The EOR smoking model was implemented in
Epicure (http://www.hirosoft.com/).
A. Main effect of genotype. The main effect of the variant
genotypes on the risk of lung cancer was estimated by odds ratios
and their 95% confidence intervals using unconditional logistic
regression analysis. Homozygosity for the more frequent allele
among controls was defined as the reference group. We tested for
significance using two-sided Wald tests. The trend test for the
effect of SNP was conducted by including the SNP variable as
continuous in logit scale in the model, and the categorical analysis
was performed by treating the SNP variable as three levels
categorical variable. Age, sex, geographical location, cumulative
smoking dose (pack-years), smoking intensity (cigarettes per day),
and quitting smoking (years since quit) were selected as covariates.
We performed stratified analyses by smoking status (never/ever) of
cases and controls and polytomous logistic regression by the major
histology types (adenocarcinoma, squamous cell carcinoma, and
small cell carcinoma) of cases. In the analysis by histology, we
defined the standard Wald chi-square test statistic using the
coefficient estimates derived from a polytomous logistic regression
(where the response variable was coded on four levels: controls,
adenocarcinoma cases, squamous cells carcinoma cases, and small
cells carcinoma cases) and the covariance matrix of the
coefficients.
B. Genotype-smoking interaction. We evaluated
genotype-smoking interactions using a likelihood ratio test to
compare the following two models:
i. Logit(LC) = a0+b6SNP+f6smoking status+c6covariates,
ii. Logit(LC) = a0+b6SNP+f6smoking status+h6SNP6smoking status
+c6covariates.
For polymorphisms showing the presence of a genotype-
smoking interaction in the association with lung cancer, we fitted
a model for the excess odds ratio of smoking (EOR) [54] in order
to separate the contribution of total exposure and intensity in the
interaction with the polymorphism. Specifically, we fitted the
following 3-parameter linear-exponential model which described
the OR in terms of continuous pack-years (d) and continuous
cigarettes per day (n): OR(d,n) = 1+b6d6g(n), where b is the EOR
at g(n)=1, i.e., the EOR/pack-year, and g(.) is a function that
describes the influence of changing cigarettes per day on the
strength of the lung cancer and pack-years association. Based on
an empirical evaluation, we used a two parameter form for g(.),
where g(n) = exp{Q16ln(n)+Q26ln(n)2}. The component, b6g(n),
describes the EOR per pack-year and its variation with cigarettes
per day and thus the influence of the delivery rate, i.e., increasing
cigarettes per day and decreasing duration of exposure. We
expanded this model to incorporate genotype (s, where s=1 and 0
denote the variant and wild type forms, respectively), using:
OR(s,d,n) = exp(as)6[1+bs6d6gs(n)], where the subscripts denote
separate parameters for each genotype. We fitted the model to
data on never and current smokers (including subjects who quit
smoking less than two years before the study) and on never and
former smokers (subjects who quit smoking more than two years
before the study), and used likelihood ratio tests to compare
homogeneity of the effects of pack-years, i.e., b1 = b0, and/or
smoking intensity, i.e., Qs = 1,1 = Qs = 0,1 and Qs = 1,2 =Qs = 0,2.
C. Joint SNPs. We analyzed multiple SNPs jointly to test
whether the overall lung cancer risk was determined by the
combined action of multiple SNPs within the same gene and/or of
multiple genes within the same pathway, even if each SNP may
have had only a modest effect size individually.
c1. Under the assumption that the effect on lung cancer of
each SNP was cumulative, we implemented the following model:
Logit LCð Þ~azb|
Xn
k
SNPkð Þzc|covariates ð1Þ
where k = 1, …, n represents a collection of SNPs belonging to the
same gene or a collection of SNPs belonging to genes in the same
pathway (e.g. phase I, n=25 i.e. all SNPs were grouped together).
SNPk=0 for the homozygote most common allele, SNPk=1 for the
heterozygote allele, and SNPk=2 for the homozygote minor allele.
b is the regression coefficient for the cumulative number of
variants Sk
n (SNPk). We estimated the overall risk of lung cancer
associated with each selected group of n SNPs by computing
OR= exp(b) in the overall population, in never smokers, and in
ever smokers separately. We estimated smoking-genotype
interaction using the likelihood ratio test. Note that in this
model we do not assume nor infer a risk direction for each minor
allele. This approach will be powerful if minor alleles for all SNPs
have effects in the same direction, but there may be loss of power if
minor alleles for some SNPs affect lung cancer risk in opposite
directions and their contribution to the overall risk cancels with
each other.
c2. For all genes represented in our data by two or more
SNPs, we computed paired linkage disequilibrium (LD) using the
Haploview software and carried out haplotype analysis using the
haplo.stats R-package.
D. Gene Expression. We evaluated to the extent possible, the
effect of polymorphisms SNPk
G from a given gene G on the gene
expression of the same gene G, and specifically the effect related to
lung cancer. We first estimated the overall effect of each group of
SNPs (SNPk
G) on lung cancer according to the additive model
Logit LCð Þ~a0z
Xn
k
bk|SNP
G
k
 
zc|covariates, ð2Þ
where bk are the n regression coefficients for the n SNPs in G.
Second, we used the bk estimated from equation (2) to compute the
overall effect of each group of polymorphisms SNPk
G on the change
of gene expression of G (ExpG) by solving the following logistic
regression:
ExpG~a1zd|
Xn
k
bk|SNP
G
k
 
: ð3Þ
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According to equation (3), d.0 indicates an increase and d,0 a
decrease in the gene expression of the gene G, due to the overall
effect of the polymorphisms SNPk
G on lung cancer. Basically, we
used the SNPs regression score for lung cancer and verified whether
it was positively or negatively associated with gene expression in non
tumor tissue samples from a subgroup of cases. Note that since we
lack gene expression data from healthy controls because no fresh
frozen lung tissue samples can be collected from healthy people, we
cannot measure directly the association between gene expression
and lung cancer risk. Combining equation (2) and (3) instead, we are
able to obtain such information. The described gene expression
analysis was performed overall and, separately, among never
smokers, former smokers, and current smokers.
E. Multiple testing and a priori knowledge considera-
tions. We considered significant those results with a p-value less
than (or equal to) 0.01. This choice was a compromise between a
more stringent Bonferroni-corrected p-value and the loss in power
from getting the threshold for significance too low. In addition, we
referred to results with p-value between 0.01 and 0.05 as
nominally significant, and considered them as notable when
consistent across different analyses. Given the number of tested
hypotheses in the single SNP analyses (25 tests corresponding to
the 25 SNPs for the single SNP analysis and 5 tests when SNPs
were grouped by genes) we took multiple testing into account. Our
approach to multiple testing was informed by the selection strategy
for the Phase I genes selected. Of note, each of the genes included
has substantial mechanistic and at least some population data
which support an association with lung cancer, as we have
described in the introduction. We recognize that quantifying this a
priori knowledge for each SNP is challenging, because of the
heterogeneity of results in the literature and because most results
actually refer to genes and not to our specific SNPs. In order to
incorporate the effect of both multiple testing and a priori
knowledge considerations, we computed the False Positive
Report Probability (FPRP) [55] to characterize the
noteworthiness for all the significant and nominally significant
results from single SNP analyses for a range of prior probabilities.
The statistical power to detect the measured OR given a type I
error rate of 0.05 was computed by means of the QUANTO
software (http://hydra.usc.edu/gxe).
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